Abuse resistant forms of immediate release hydromorphone, method of use and method of making

1. A method of treating pain in a patient in need thereof, comprising:

orally administering to the patient an abuse resistant immediate release pharmaceutical composition containing a drug selected from the group consisting of any one or more of hydromorphone, morphine, oxycodone and pharmaceutically acceptable salts thereof in tablet dosage form, wherein the tablet dosage form comprises the following tablet layers:

an innermost expansion layer that does not contain any drug and comprises an expandable polymer selected from the group consisting of hydroxypropylmethylcellulose and polyacrylic acid,

a barrier layer that substantially covers the expansion layer and comprises a first polymer that does not substantially dissolve in the gastrointestinal (GI) tract, wherein the first polymer is selected from the group consisting of polyacrylates and polyethylene glycol, and

a diffusion layer that substantially covers and is bonded to the barrier layer and comprises said drug substantially homogeneously distributed within a second polymer selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethylcellulose, quaternary ammonium acrylic or methacrylic polymers, cellulose acetate phthalate, and polyvinyl alcohol and mixtures thereof, wherein the drug diffuses from the diffusion layer within the GI tract to treat pain,

wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is physically compromised to produce particles having a particle size between 8 mesh and 500 mesh and exposed to a liquid comprising water and/or alcohol, the bond between the diffusion later and the barrier layer is substantially preserved and the expandable polymer of the expansion layer absorbs at least a portion of the liquid and expands and/or forms a gel,

wherein the diffusion layer is the only drug containing layer.

2. The method of claim 1 , wherein the pharmaceutical composition is independent of pH in its release profile.

3. The method of claim 1 , wherein the expansion layer further comprises a disintegrant comprising croscarmellose sodium or sodium starch glycolate.

4. The method of claim 1 , where in the barrier layer covers more than 95% of the expansion layer.

5. The method of claim 1 , wherein the drug is hydromorphone or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the drug is oxycodone or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the drug is morphine or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the diffusion layer is applied immediately after the barrier layer is applied and curing them together.

9. The method of claim 1 , wherein when the pharmaceutical composition is administered in intact form at least 90% of the drug is released after one hour, whereas when the pharmaceutical composition is administered in compromised form no more than 60% of the drug is released in one hour.

10. The method of claim 9 , wherein the administration of the pharmaceutical composition in compromised form comprises crushing the tablet and then snorting, swallowing or injecting the crushed tablet.

11. The method of claim 9 , wherein said administration in compromised form results in a reduced Cmax of the drug causing a reduced euphoria.

12. The method of claim 1 , wherein the drug is morphine sulfate.

13. The method of claim 1 , wherein the drug is oxycodone hydrochloride.

14. The method of claim 1 , wherein the drug is hydrocodone bitartrate.

15. The method of claim 1 , wherein the drug is hydrocodone hydrochloride.